Full-Time
Assistant Product Manager
Neuromuscular Franchise
Posted on 8/17/2026
Biogen
5,001-10,000 employees
Develops therapies for neurological disorders
No salary listed
Paris, France
In Person
Master's
 Business & Strategy (1) |
|---|
Get referred to Biogen
See people who can refer or advise you
- A Bac+5 scientific education in Pharmacy, Life Sciences, or a related scientific field is required.
- The candidate must have initial marketing experience, ideally in the pharmaceutical industry, through an internship, alternance, or first job.
- The candidate must understand regulated environments and have an interest in pharmaceutical processes.
- The candidate must be able to organize work and manage multiple projects simultaneously.
- The candidate must work effectively in cross-functional environments.
- The candidate must be fluent in French and English.
- Support the marketing manager and franchise director in defining the marketing and commercial strategy.
- Develop and support the deployment of marketing tactics that address strategic priorities.
- Develop services that improve care for patients with rare neuromuscular diseases or support the organization of care.
- Develop and deploy product marketing tools and multichannel materials adapted to local regulatory and customer requirements, in strong collaboration with Medical, Innovation, Digital, and Market Access departments.
- Train field teams on marketing campaigns and tools, and analyze their implementation for continuous improvement.
- Support coordination of all marketing activities at regional and national congresses, including strategic congress briefs, booth location and construction, documentation selection, and symposium organization.
- A dual scientific and marketing course of study or a business-school background is an advantage.
- Previous marketing experience in the pharmaceutical industry is preferred.
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $2.74 billion, up 3%, beating estimates.
- LEQEMBI global sales hit $184 million; U.S. sales reached $97 million.
- RayThera closes in Q3 2026, adding immunology pipeline depth.
What critics are saying
- Italy's AGCM opened a Biogen antitrust probe on 2026-05-19.
- Sandoz's Tyruko undercuts Tysabri by 20%, pressuring Biogen's MS pricing.
- Diranersen missed its primary endpoint, so Phase 3 can still fail.
What makes Biogen unique
- Biogen and Eisai won FDA approval for LEQEMBI IQLIK on 2026-07-28.
- Biogen's growth portfolio topped its multiple sclerosis franchise in Q2 2026.
- Diranersen showed 50-65% CSF tau reduction at AAIC 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -11%1 year growth
↓ -11%2 year growth
↓ -11%Formation Bio names Michael Ehlers Chief Scientific Officer and Head of R&D. Published. August 11, 2026 Formation Bio has appointed Michael D. Ehlers, MD, PhD, as Chief Scientific Officer and Head of Research and Development. He will lead the AI-focused pharmaceutical company's scientific and clinical strategy across its drug portfolio. Ehlers will oversee portfolio selection and advancement from translational research through clinical development. He will also guide the scientific direction of Formation Bio's proprietary AI platform. Ehlers joins from MPM BioImpact, where he served as entrepreneur partner. He previously founded four biotechnology companies as partner and chief scientific officer at Apple Tree Partners. Three have advanced to the clinical stage, including Ascidian Therapeutics, which Ehlers led as founding chief executive officer. Earlier, Ehlers served as executive vice president of research and development at Biogen. At Pfizer, he was group senior vice president of biotherapeutics research and chief scientific officer for neuroscience. Programs advanced under his leadership have produced six approved drugs spanning five indications and four therapeutic modalities. More than 40 additional programs have entered clinical trials. "Mike has operated at this intersection his entire career, and he's going to be central to how we pick, design, and progress programs," said Formation Bio Co-Founder and CEO Benjamine Liu. Before entering the biotechnology industry, Ehlers was a neurobiology professor and Howard Hughes Medical Institute investigator at Duke University Medical Center. He holds a bachelor's degree in chemistry from Caltech and medical and doctoral degrees from Johns Hopkins School of Medicine.
Biocon announces commercial launch of Yesafili in USA. 7 August 2026 India's Biocon (BSE: 5325) has announced the commercial launch of Yesafili (aflibercept-jbvf) in the USA. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2-mg, originated by US biotech Regeneron (Nasdaq: REGN) and licensed to Germany's Bayer (BAYN: DE). The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws. However, Biogen only reached an agreement with Regeneron to launch the biosimilar in the second half of 2026. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 21 May 2024 24 October 2024 17 April 2025 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 7 August 2026 Company spotlight. A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus. More features in biosimilars. 5 August 2026 31 July 2026 23 July 2026 22 July 2026
Stifel Nicolaus remains a Buy on Biogen (BIIB). Aug. 2, 2026, 11:05 AM Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $242.00. * Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions * Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks According to TipRanks, Matteis is a 5-star analyst with an average return of 16.7% and a 52.83% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes. In addition to Stifel Nicolaus, Biogen also received a Buy from Truist Financial's Danielle Brill in a report issued on July 31. However, on the same day, Wedbush assigned a Hold rating to Biogen (NASDAQ: BIIB). Based on Biogen's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.74 billion and a net profit of $97.5 million. In comparison, last year the company earned a revenue of $2.65 billion and had a net profit of $634.8 million Read More on BIIB:
Biogen beats estimates as new medicines overtake multiple sclerosis business. 29 Jul 2026, 11:33 pm Pedestrians walk past Biogen Inc headquarters in Cambridge, Massachusetts. Biogen CEO Christopher Viehbacher said in a statement, noting that sales of the company's newer medicines now exceed those of its older multiple sclerosis franchise. (July 29): Biogen Inc reported quarterly revenue and adjusted earnings that beat analysts' expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines. The company raised its revenue outlook for the year, saying sales are now expected to grow by a mid-single-digit percentage instead of declining by a mid-single-digit percentage as previously forecast. However, Biogen lowered its adjusted earnings guidance to reflect acquisition-related costs and milestone payments. Under chief executive officer Christopher Viehbacher, Biogen has gone on an aggressive acquisition strategy to expand beyond its historic neurology focus and come up with sources of new growth to replace the company's ageing portfolio of multiple sclerosis drugs. That has brought it into new therapeutic areas such as kidney disease and immunology. The exclusive allure of owning the shore Minor International's Anantara Desaru Coast Residences, the first beachfront branded residences in Malaysia, offer fully furnished villas with stunning sea views and access to resort facilities, blending luxury living with sustainability. Biogen has made "significant progress" repositioning the company for growth, Viehbacher said in a statement, noting that sales of the company's newer medicines now exceed those of its older multiple sclerosis franchise, whose revenues continue to decline. Sales of Leqembi for Alzheimer's disease, a key drug that the company sells through a partnership with Eisai Co, grew 15% in the quarter to US$184 million (RM752.03 million), roughly in line with analyst expectations. Biogen's solid results were "driven by a good quarter across the majority of its key growth products," RBC Capital Markets analyst Brian Abrahams said in a note to clients. Biogen shares rose 4.7% at 9.40am in New York. The shares had increased 17% this year through the close of trading on Tuesday, outpacing the S&P 500 Index. In May, the company closed its US$5.6 billion acquisition of Apellis Pharmaceuticals Inc, whose portfolio includes Syfovre for an immune disorder that causes blindness and Empaveli for a rare blood disorder and certain rare kidney diseases. The two medications brought in almost US$128 million in revenue to Biogen during the remainder of the quarter, the company said. Biogen lowered its adjusted earnings forecast for the year to US$12 to US$13 a share from US$14.25 to US$15.25, reflecting expected charges for acquired research and development, milestone payments and financing costs related to the Apellis deal. Excluding those items, the company's underlying earnings outlook would have increased by 60 cents a share, Biogen said. Biogen announced in June that it would acquire RayThera Inc, a closely held developer of immunology drugs, for as much as US$1 billion. Several other newer medicines also posted strong quarterly growth. Sales of Zurzuvae, a treatment for postpartum depression, jumped 53% to US$71 million, while Skyclarys, for the rare disease Friedreich's ataxia, climbed to about US$168 million, beating analysts' expectations. Uploaded by Felyx Teoh
Biogen reported second-quarter results exceeding Wall Street expectations, with revenue rising 3% year-over-year to $2.74 billion, above the $2.47 billion consensus estimate. Adjusted earnings reached $3.60 per share, beating forecasts of $2.89. The company's Growth Portfolio generated $1.06 billion in revenue, up 24% and surpassing its multiple sclerosis franchise for the first time. Alzheimer's treatment Leqembi recorded $184 million in global sales, whilst Skyclarys revenue jumped 29% to $168 million and Zurzuvae climbed 53% to $71 million. Biogen raised its 2026 underlying earnings guidance to $15.85–$16.85 per share, up from $15.25–$16.25 previously. The company expects full-year revenue to increase by a mid-single-digit percentage.